Skunkworx Bio develops novel therapeutic agents by identifying and modulating protein-protein interaction "HotSpots" using its proprietary Pocket Biologics platform. This integrated computational and wet-lab approach enables the rapid creation of highly specific small protein scaffolds for drug discovery, supporting the development of next-generation biologics.
Funding
Funding not disclosed
Founders
Product
Problem
Developing novel therapeutic agents targeting protein-protein interactions (PPIs) is challenging due to the complexity of identifying and modulating these interaction sites. Traditional methods often struggle to precisely differentiate disease-relevant hotspots from non-specific binding sites, leading to inefficient drug lead identification and validation.
Solution
Skunkworx Bio develops proprietary Pocket Biologics, which are small, stable protein scaffolds designed for therapeutic applications. Their platform integrates computational bioinformatics with wet-lab design to analyze protein-protein interactions and identify pharmacologically active "HotSpots." This approach enables the rapid differentiation of disease-relevant hotspots, facilitating the development of validated drug leads that can act as either agonists or antagonists for diverse disease targets. The technology supports the creation of next-generation biologics, including targeted bispecifics, CAR-T applications, and pocket-drug conjugates.
Target Audience
The primary target audience includes pharmaceutical and biotechnology companies engaged in drug discovery and development, particularly those focusing on protein-protein interaction targets and novel biologic modalities.
Features
- Proprietary Pocket Biologics platform utilizing small (2–15 kDa) protein scaffolds for therapeutic development.
- Identification and differentiation of protein-protein interaction HotSpots using integrated bioinformatic analysis and wet-lab screening.
- Computational methods for target druggability assessment and lead optimization.
- Generation of novel composition of matter drug candidates with exquisite target specificity.
- Capability to develop both agonist and antagonist molecules for various disease indications.
- Application in next-generation biologics, including targeted bispecifics, pocket-drug conjugates, and CAR-T therapies.